Bioinformatics approach to identify molecular targets of chrysin against Alzheimer's disease

被引:0
|
作者
Gezici, Sevgi [1 ,3 ]
Sekeroglu, Nazim [2 ,3 ]
机构
[1] Gaziantep Univ, Fac Med, Dept Med Biol & Genet, TR-27310 Gaziantep, Turkiye
[2] Gaziantep Univ, Fac Sci & Literature, Dept Biol, TR-27310 Gaziantep, Turkiye
[3] Gaziantep Univ, Phytotherapy & Med Aromat Plants Applicat & Res Ct, Gaziantep 27310, Turkiye
来源
关键词
Pharmacokinetic properties; Chrysin; Molecular pathway; Protein network; Drug-likeness; PARKINSON;
D O I
10.54085/ap.2023.12.1.38
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chrysin is a natural compound with numerous pharmacological properties, especially antioxidant, antiinflammatory, antiviral, antitumor, anticancer, and hepatoprotective activities. Although, the biological activities of chrysin have been described and its possible pharmacological properties have been previously determined, its pharmacokinetic properties against Alzheimer's disease (AD) have not been fully elucidated based on gene targets, drug-likeness, molecular signaling pathways, and network-based pharmacology analyses. In this study, we aimed to reveal the molecular targets and potential interactions of chrysin against AD by gene-set enrichment and bioinformatics approach. The chrysin was entered into the PubChem and ChEBI database, and the targets of chrysin were estimated using DIGEP-Pred. Then, GeneCards, DisGeNET, PharmGKB, and Swiss Target Prediction were used to identify possible interacting genes and proteins. The drug-likeness properties and toxicity characteristics of chrysin were determined using Swiss ADME and ProToxII databases. In addition, STRING and KEGG enrichment database were used to elucidate the role of probable interacting proteins to construct a protein-protein interaction (PPI) network and a network of molecular targeting pathways, respectively. Based on the results of pharmacokinetic properties and drug-likeness analysis, chrysin predicted to have a good drug-likeness activity (score = - 0.21), as well as good brain barrier permeability (BBB score = 3.71) with no observable toxicity. A total of 38 genes were identified as the top genes that interact with chrysin against Alzheimer's disease. ILB, IL6, TNF, MAPK1, CASP3, PSEN1, PSEN2, PTGS2, NFKB1, AKT1, GSK3B, and APP were selected as top core targets that may play a significant role in AD treatment. Furthermore, a total of 158 different pathways were identified as the probably modulated pathways, corresponding to 38 protein targets. Besides neurodegeneration and AD, pathways in cancer, lipid and atherosclerosis, EGFR tyrosine kinase inhibitor resistance, AGE-RAGE signaling in diabetic complications, HIF-1 signaling, PI3K-Akt signaling, MAPK signaling, IL-17 signaling, neurotrophin and sphingolipid signaling were defined as the top pathways associated with chrysin-regulated proteins. Overall, the results indicated that the network-based approach could provide a novel approach to uncover the therapeutic mechanisms of chrysin against AD.
引用
收藏
页码:259 / 268
页数:10
相关论文
共 50 条
  • [11] Exploring the molecular targets for Type 2 diabetes-induced Alzheimer's disease through bioinformatics analysis
    Gao, Lin
    Huang, Chengyu
    Li, Hui
    Wu, Shidi
    Zhou, Xiaoyan
    Ying, Changjiang
    [J]. EPIGENOMICS, 2023, 15 (11) : 619 - 633
  • [12] Molecular and Therapeutic Targets of Genistein in Alzheimer’s Disease
    Kasi Pandima Devi
    Balakrishnan Shanmuganathan
    Azadeh Manayi
    Seyed Fazel Nabavi
    Seyed Mohammad Nabavi
    [J]. Molecular Neurobiology, 2017, 54 : 7028 - 7041
  • [13] Molecular Targets of Tannic Acid in Alzheimer's Disease
    Braidy, Nady
    Jugder, Bat-Erdene
    Poljak, Anne
    Jayasena, Tharusha
    Nabavi, Seyed Mohammad
    Sachdev, Perminder
    Grant, Ross
    [J]. CURRENT ALZHEIMER RESEARCH, 2017, 14 (08) : 861 - 869
  • [14] Alzheimer's disease: molecular concepts and therapeutic targets
    Fassbender, K
    Masters, C
    Beyreuther, K
    [J]. NATURWISSENSCHAFTEN, 2001, 88 (06) : 261 - 267
  • [15] An in silico approach to identify potential downstream targets of miR-153 involved in Alzheimer's disease
    Amber, Sanila
    Zahid, Saadia
    [J]. FRONTIERS IN GENETICS, 2024, 15
  • [16] Alzheimer's disease: Molecular concepts and therapeutic targets
    Fassbender K.
    Masters C.
    Beyreuther K.
    [J]. Naturwissenschaften, 2001, 88 (6) : 261 - 267
  • [17] Emerging molecular targets - A key to Alzheimer's disease?
    Gurwitz, D
    [J]. DRUG DISCOVERY TODAY, 1998, 3 (03) : 144 - 144
  • [18] Molecular drug targets and therapies for Alzheimer's disease
    Singh, Dev Bukhsh
    Gupta, Manish Kumar
    Kesharwani, Rajesh Kumar
    Sagar, Mamta
    Dwivedi, Seema
    Misra, Krishna
    [J]. TRANSLATIONAL NEUROSCIENCE, 2014, 5 (03) : 203 - 217
  • [19] Molecular and Therapeutic Targets of Genistein in Alzheimer's Disease
    Devi, Kasi Pandima
    Shanmuganathan, Balakrishnan
    Manayi, Azadeh
    Nabavi, Seyed Fazel
    Nabavi, Seyed Mohammad
    [J]. MOLECULAR NEUROBIOLOGY, 2017, 54 (09) : 7028 - 7041
  • [20] Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer's Disease
    Khadgawat, Priya
    Siddesha, J. M.
    Shashank, Dharini
    Prasad, Shashanka K.
    [J]. JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2021, 5 (01) : 405 - 411